Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Pelthos Therapeutics Inc. (PTHS : AMEX)

• Company Description    Pelthos Therapeutics is a biopharmaceutical company. Its lead product includes ZELSUVMI(TM) topical gel. Pelthos Therapeutics, formerly known as Channel Therapeutics Corporation, is based in DURHAM, N.C. Number of Employees: 92

• Price / Volume Information    Yesterday's Closing Price: $26.66 Daily Weekly Monthly 20 Day Moving Average: 26,701 shares Shares Outstanding: 3.48 (millions) Market Capitalization: $92.66 (millions) Beta: 3.29 52 Week High: $37.50 52 Week Low: $9.00 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 14.91% 9.30% 12 Week 15.91% 7.16% Year To Date -14.00% -19.63%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 4020 STIRRUP CREEK DRIVE SUITE 110 - DURHAM,NC 27703 USA ph: 919-908-2400 fax: - mmoyer@lifesciadvisors.com http://www.pelthos.com

• General Corporate Information    Officers Scott Plesha - Chief Executive Officer and President Peter Greenleaf - Chairman Francis Knuettel - Chief Financial Officer Andrew Einhorn - Director Todd Davis - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 171126204 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/12/26 Share - Related Items Shares Outstanding: 3.48 Most Recent Split Date: 7.00 (0.10:1) Beta: 3.29 Market Capitalization: $92.66 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-3.02 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-11.70 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.64 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 3.44% vs. Previous Quarter: -9.19% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: 16.16% ROE 03/31/26 - -123.54 12/31/25 - -141.43 09/30/25 - -210.32 ROA 03/31/26 - -38.54 12/31/25 - -47.28 09/30/25 - -72.82 Current Ratio 03/31/26 - 2.79 12/31/25 - 2.05 09/30/25 - 2.01 Quick Ratio 03/31/26 - 1.86 12/31/25 - 1.15 09/30/25 - 1.04 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - -212.90 12/31/25 - -301.91 09/30/25 - -324.68 Book Value 03/31/26 - 10.10 12/31/25 - 12.02 09/30/25 - 18.99 Inventory Turnover 03/31/26 - 0.32 12/31/25 - 0.33 09/30/25 - 0.38 Debt-to-Equity 03/31/26 - 1.41 12/31/25 - 0.81 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 58.58 12/31/25 - 44.71 09/30/25 - 0.00

Powered by Zacks Investment Research ©